2023³â ICH °¡À̵å¶óÀÎ ±³À° Day 1 - Quality&Multidisciplinary ÀÚ·áÁýÀÔ´Ï´Ù.
¾Æ·¡ °¿¬ÀÇ °¿¬ÀÚ·á(°ø°³¹öÀü)°¡ ÷ºÎÆÄÀÏ·Î ¾÷µ¥ÀÌÆ® µÇ¾úÀ¸´Ï ´Ù¿î·Îµå ÇϽþî Âü°íÇϽñ⠹ٶø´Ï´Ù.
[ ver.231023 ¾÷µ¥ÀÌÆ® ÀÚ·á ¸ñ·Ï ]
#1_[ICH] Á¤Áö¿ø (NIFDS): Çѱ¹ÀÇ ICH È°µ¿ ¹× °¡À̵å¶óÀÎ ÀÌÇà ÇöȲ
#2_[Q2(R2)/Q14] Yukio Hiyama (NIHS): Validation of Analytical Procedure(Q2(R2)) and Analytical Development(Q14)
#3_[Q2(R2)/Q14] ÀÌ¿µÇÊ (ÁøÄÚ¾î): ¹ÙÀÌ¿ÀÀǾàÇ° °³¹ß¿¡¼ ºÐ¼®¹ýÀÇ ¿ªÇÒ
#4_[Q3] Gair Ford (AstraZeneca): ICH Q3 Guidelines - Update on formal guidance and industry activities to support risk assessment
#5_[M7/M7 Q&As] ±èÁÖ¹Ì (Áö³ªÆнº): ICH M7(R2) °¡À̵å¶óÀÎ °³¿ä ¹× ÇöȲ
#6_[M10/M10 Q&As] ¹®ÁÖ¿¬ (ÀÎÅͳ׼ųλçÀ̾ðƼÇȽºÅÄ´Ùµå(ISS)): ICH M10 °¡À̵å¶óÀÎ ¹× ÀÌÇà½Ã °í·Á»çÇ×
¡Øº» °¿¬ÀÚ·á ¹«´Ü º¹Á¦ ¹× ¹èÆ÷´Â ±ÝÁöµÇ¾î ÀÖÀ¸¸ç, À§¹Ý ½Ã ¹ýÀû ó¹úÀ» ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.
°¨»çÇÕ´Ï´Ù.
¹®ÀÇ : edu@kobia.kr